Merus B.V. is a clinical-stage immuno-oncology company developing bispecific antibody therapeutics, referred to as Biclonics. The company's bispecific antibody candidate, MCLA-128, is being evaluated in a Phase 1/2 clinical trial as a potential treatment for HER2-expressing solid tumors; MCLA-117, is being developed as a potential treatment for acute myeloid leukemia and MCLA-158, which is designed to bind to cancer stem cells and is being developed as a potential treatment for colorectal cancer and other solid tumors. Merus B.V. is headquartered in Utrecht, the Netherlands.
| Revenue (Most Recent Fiscal Year) | $36.13M |
| Net Income (Most Recent Fiscal Year) | $-215.33M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 70.02 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 6.43 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -490.45% |
| Net Margin (Trailing 12 Months) | -506.73% |
| Return on Equity (Trailing 12 Months) | -35.99% |
| Return on Assets (Trailing 12 Months) | -29.83% |
| Current Ratio (Most Recent Fiscal Quarter) | 5.86 |
| Quick Ratio (Most Recent Fiscal Quarter) | 5.86 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $8.61 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-1.40 |
| Earnings per Share (Most Recent Fiscal Year) | $-2.84 |
| Diluted Earnings per Share (Trailing 12 Months) | $-4.08 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 69.21M |
| Free Float | 66.05M |
| Market Capitalization | $3.83B |
| Average Volume (Last 20 Days) | 1.54M |
| Beta (Past 60 Months) | 0.94 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 4.57% |
| Percentage Held By Institutions (Latest 13F Reports) | 96.14% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |